Illumina

YTD

ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R.

CEO

Jacob Thaysen

CEOJacob Thaysen

Employees

8,600

Employees8,600

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

8,600

Employees8,600

ILMN Key Statistics

Market cap

24.87B

Market cap24.87B

Price-Earnings ratio

29.58

Price-Earnings ratio29.58

Dividend yield

—

Dividend yield—

Average volume

1.69M

Average volume1.69M

High today

$165.97

High today$165.97

Low today

$160.84

Low today$160.84

Open price

$161.19

Open price$161.19

Volume

2.17M

Volume2.17M

52 Week high

$165.97

52 Week high$165.97

52 Week low

$78.79

52 Week low$78.79

Stock Snapshot

The current Illumina(ILMN) stock price is $164.40, with a market capitalization of 24.87B. The stock trades at a price-to-earnings (P/E) ratio of 29.58.

On 2026-06-01, Illumina(ILMN) stock moved within a range of $160.84 to $165.97. With shares now at $164.40, the stock is trading +2.2% above its intraday low and -0.9% below the session's peak.

Trading volume for Illumina(ILMN) stock has reached 2.17M, versus its average volume of 1.69M.

The stock's 52-week range extends from a low of $78.79 to a high of $165.97.

ILMN News

TipRanks 6h

Integrated DNA Technologies enters collaboration with Illumina

Integrated DNA Technologies (DHR) announced a strategic collaboration with Illumina (ILMN) to enable a DRAGEN secondary analysis pipeline for IDT xGen FFPE and...

Investing.com 7h

IDT partners with Illumina on oncology research workflow - Investing.com

...

TipRanks 8h

Illumina price target raised to $180 from $170 at Guggenheim

Guggenheim raised the firm’s price target on Illumina (ILMN) to $180 from $170 and keeps a Buy rating on the shares after having hosted the CFO and IR team for...

Analyst ratings

52%

of 23 ratings

Buy

52.2%

Hold

26.1%

Sell

21.7%

More ILMN News

Simply Wall St 2d

Is It Too Late To Reassess Illumina After A 98% One Year Surge?

Wondering if Illumina at US$162.96 is priced for growth or still leaving some value on the table? This article walks through what the current share price might...

Simply Wall St 4d

Assessing Illumina Valuation After Its New MRD Research Solution Expands Oncology Offering

Advertisement Why Illumina’s new MRD kit matters for the stock Illumina (ILMN) has drawn fresh attention after launching a whole genome based molecular residu...

TipRanks 6d

Illumina Shareholders Back Board, Auditor and Executive Pay

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.